timh
10-08-05, 06:17 PM
Here is a group of quick facts for those that are just starting to take Strattera (information is taken from the Strattera website).
Please refer to Strattera Prescribing Information (http://pi.lilly.com/us/strattera-pi.pdf) for a complete list or talk with your prescribing doctor.
Dosing:
STRATTERA capsules are intended for oral administration only.
STRATTERA is not a controlled substance.
Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40 or 60 mg of atomoxetine.
STRATTERA can be administered with or without food.
Children (up to 70kg body weight): STRATTERA should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. The total daily dose in children and adolescents should not exceed 1.4 mg/kg or 100 mg,whichever is less.
Children and Adults (70kg and over): STRATTERA should be initiated at a total daily dose of 40 mg and increased after a minimum of 3 days to a target total daily dose of approximately 80 mg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. After 2 to 4 additional weeks, the dose may be increased to a maximum of 100 mg in patients who have not achieved an optimal response. The maximum recommended total daily dose in children and adolescents over 70 kg and adultsis 100 mg.
Atomoxetine can be discontinued without being tapered.
Possible Side Effects (denotes most commonly reported on ADDFORUMS):
Abdominal pain (upper)
Constipation
Appetite decreased
Irritability
Dry mouth
Nausea
Fatigue
Heart Palpitations
Insomnia
Urinary hesitation and/or urinary retention
Erectile disturbance
Ejaculation failure/premature
Impotence
Sweating increased
Hot flushes
Vivid dreams (not reported on Strattera website)
Precautions:
STRATTERA should be used with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease because it can increase blood pressure and heart rate.
In adult ADHD controlled trials, the rates of urinary retention (3%, 7/269) and urinary hesitation (3%, 7/269) were increased among atomoxetine subjects compared with placebo subjects (0%, 0/263).
In general, the weight and height gain of pediatric patients treated with STRATTERA lags behind that predicted by normative population data for about the first 9-12 months of treatment.
Although there is no conclusive evidence that STRATTERA causes aggressive behavior or hostility, aggressive behavior or hostility was more frequently observed in clinical trials among children and adolescents treated with STRATTERA compared to placebo (overall risk ratio of 1.33 – not statistically significant). Patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.
Warnings:
Lilly Announces Important Strattera® Label Update (http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=175142)
Please refer to Strattera Prescribing Information (http://pi.lilly.com/us/strattera-pi.pdf) for a complete list or talk with your prescribing doctor.
Dosing:
STRATTERA capsules are intended for oral administration only.
STRATTERA is not a controlled substance.
Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40 or 60 mg of atomoxetine.
STRATTERA can be administered with or without food.
Children (up to 70kg body weight): STRATTERA should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. The total daily dose in children and adolescents should not exceed 1.4 mg/kg or 100 mg,whichever is less.
Children and Adults (70kg and over): STRATTERA should be initiated at a total daily dose of 40 mg and increased after a minimum of 3 days to a target total daily dose of approximately 80 mg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. After 2 to 4 additional weeks, the dose may be increased to a maximum of 100 mg in patients who have not achieved an optimal response. The maximum recommended total daily dose in children and adolescents over 70 kg and adultsis 100 mg.
Atomoxetine can be discontinued without being tapered.
Possible Side Effects (denotes most commonly reported on ADDFORUMS):
Abdominal pain (upper)
Constipation
Appetite decreased
Irritability
Dry mouth
Nausea
Fatigue
Heart Palpitations
Insomnia
Urinary hesitation and/or urinary retention
Erectile disturbance
Ejaculation failure/premature
Impotence
Sweating increased
Hot flushes
Vivid dreams (not reported on Strattera website)
Precautions:
STRATTERA should be used with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease because it can increase blood pressure and heart rate.
In adult ADHD controlled trials, the rates of urinary retention (3%, 7/269) and urinary hesitation (3%, 7/269) were increased among atomoxetine subjects compared with placebo subjects (0%, 0/263).
In general, the weight and height gain of pediatric patients treated with STRATTERA lags behind that predicted by normative population data for about the first 9-12 months of treatment.
Although there is no conclusive evidence that STRATTERA causes aggressive behavior or hostility, aggressive behavior or hostility was more frequently observed in clinical trials among children and adolescents treated with STRATTERA compared to placebo (overall risk ratio of 1.33 – not statistically significant). Patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.
Warnings:
Lilly Announces Important Strattera® Label Update (http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=175142)